Though some areas of SENS, such as stem cells and amyloid immunotherapy, are sufficiently mainstream not to need funding, most are still relative backwaters that rely on the Methuselah Foundation to progress. As a result of the great generosity of donors, the non-profit organization trebled the diversity of its research in 2008. At the BIL unconference in February, Chief Science Officer Aubrey de Grey gave an overview of the research projects that the organization is now funding, their significance to SENS, and their potential to lead to accelerated progress towards the defeat of aging in 2009 and beyond.
Convergence08, the interdisciplinary unconference, continued with a panel discussion on life extension. Moderated by Christine Peterson of Foresight Nanotech Institute, the group of biotechnology and health experts included Aubrey de Grey of the Methuselah Foundation, Terry Grossman of the Frontier Medical Institute, Bruce Ames of the Children’s Hospital Oakland Research Institute, and Gregory Benford of Genescient Corporation.
Aubrey de Grey of the Methuselah Foundation and Tanya Jones of Alcor Life Extension
The free public event preceding the Understanding Aging conference organized by the Methuselah Foundation was entitled “Aging: the disease, the cure, the implications.” Held in Royce Hall at UCLA on the evening of June 27th, 2008, the event aimed at putting the postponement of aging more firmly on the political and social map than ever before. There, biogerontologist Aubrey de Grey offered his own underlying arguments for why aging can and should be the target of current-day regenerative medicine.
The Methuselah Foundation is a 501c(3) non-profit organization committed to the acceleration of progress toward a cure for age-related disease. Biogerontologist Aubrey de Grey has formulated a wide-ranging plan for the comprehensive and eventually indefinite postponement of age-related physical and mental decline, named Strategies for Engineered Negligible Senescence. He is the organizer of an ongoing series of conferences and workshops that focus on the key biomedical research relevant to SENS, the most recent of which was entitled “Aging: the disease, the cure, the implications.”
Aubrey de Grey is the Chair and Chief Science Officer of the Methuselah Foundation, a non-profit organization dedicated to combating the aging process. In this talk presented at the February Silicon Valley transhumanist meetup, he outlined the several most notable developments in funding and research taking place at the Methuselah Foundation in late 2007 and early 2008.
Aubrey de Grey is the editor-in-chief of Rejuvenation Research, a medical journal which publishes cutting-edge work on anti-aging therapies in the laboratory and clinic. At the “Securing the Longevity Dividend” event in Chicago organized by the Institute for Ethics and Emerging Technologies, he argued the scientific feasibility of anti-aging therapies by exploring the concept of longevity escape velocity and sharing interim results from research funded by the Methuselah Foundation.
The Methuselah Foundation held an informal dinner conversation on October 19 to discuss the effort to secure biotechnological strategies for engineered negligible senescence. Questions were fielded by Aubrey de Grey, Chairman and Chief Science Officer of the Methuselah Foundation. Continued from “The Effort to Postpone Frailty Indefinitely“
The Methuselah Foundation held an informal dinner conversation on October 19 to discuss the effort to secure biotechnological strategies for engineered negligible senescence. Questions were fielded by Aubrey de Grey, Chairman and Chief Science Officer of the Methuselah Foundation. Participants included Jeffrey Hall, Executive Director of SENS, and Allison Taguchi, the Development Officer of the Methuselah Foundation. The event itself was organized by Bruce Klein and Susan Fonseca-Klein of the Immortality Institute.
Aubrey de Grey is a biomedical gerontologist seeking a cure for human aging. He has recently published a book on the topic entitled Ending Aging: The Rejuvenation Breakthroughs That Could Reverse Human Aging in Our Lifetime. He is open and supportive of his arrangements to be cryopreserved with Alcor Life Extension, and at the 7th Alcor Conference in Scottsdale, Arizona he discussed his decision to make it known in a presentation entitled “Is It Safe for a Biologist to Support Cryonics Publicly?”
SIAI Interview Series – Aubrey de Grey
Aubrey de Grey presenting at the 6th Alcor Conference in Scottsdale
Aubrey de Grey is the editor of Rejuvenation Research, the world’s only peer-reviewed journal focused on intervention in aging, he is an advocate of research seeking answers to how molecular and cellular metabolic damage brings about aging and ways humans can intervene to repair and/or obviate that damage. At the 2006 Alcor conference in Scottsdale, Arizona, he gave a presentation on how implementing Strategies for Engineered Negligible Senescence might be viewed as a precursor to the prospect of reviving patients from cryonic suspension.
The central goal of Aubrey de Grey’s work is to expedite the development of a true cure for human aging. As a scientist with a training in an engineering discipline (computer science), he believes himself to be well placed to bridge this gap. Continued from “The Mythical Merits of Mealy-Mouthed Messaging: Part One.”